ARTH - Arch Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.5510
-0.0370 (-6.29%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close0.5880
Open0.0000
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume273,658
Market Cap88.461M
Beta (3Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-0.041
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.27
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the 510(k) premarket notification for AC5™ Topical Gel has been reviewed and cleared by the U.S. Food and Drug Administration (FDA), allowing for the product to be marketed. AC5 Topical Gel is a topical dressing indicated for use in the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. Marketing clearance, which requires the provision of necessary documentation and data to the FDA, is an essential milestone to the path to commercialization.

  • GlobeNewswire13 days ago

    Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, presented an update on its corporate milestones, plans and timetables at the LD Micro Main Event XI in Los Angeles, California. Chief Executive Officer, Terrence W. Norchi, MD provided the following summary.

  • GlobeNewswire15 days ago

    Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court

    FRAMINGHAM, Mass., Dec. 04, 2018 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,.

  • GlobeNewswire21 days ago

    Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe

    Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company has submitted the required documents for AC5™ Topical Hemostat (AC5)1 to its Notified Body as it seeks a CE mark, which is a next step on the path to commercialization in countries governed by the European Medical Devices Directive (MDD). This first such submission by Arch to a European regulatory body follows the recent submission of a 510(k) premarket notification to the US Food and Drug Administration. Receipt of a CE mark would allow AC5 to be commercialized for use on external wounds, and in particular, for controlling bleeding by mechanically sealing areas of leakage and managing wounds in skin.

  • GlobeNewswire23 days ago

    Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018

    Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the LD Micro Main Event XI. Chief Executive Officer, Terrence W. Norchi, MD will deliver a corporate presentation on Tuesday, December 4 at 12:00 PM Pacific Time in Track 1.

  • GlobeNewswire3 months ago

    Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5™ Topical Gel

    Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company submitted a 510(k) notification to the U.S. Food and Drug Administration (FDA or “the Agency”) for its AC5ä Topical Gel (AC5)1 and has received acknowledgement from the Agency that the submission has been received. The purpose of the 510(k) notification is to allow for commercial use of AC5 on external wounds for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. Terrence W. Norchi, MD, President and CEO of Arch, said, “We are happy to have initiated and completed the necessary steps required to file this submission during the third calendar quarter.

  • GlobeNewswire3 months ago

    Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018

    FRAMINGHAM, Mass., Sept. 25, 2018-- Arch Therapeutics, Inc., developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the Ladenburg Thalmann ...

  • OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
    PR Newswire9 months ago

    OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

    OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for ...